Navigation Links
Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
Date:3/22/2013

domized, double-blind, placebo-controlled, dose-ranging trial to evaluate the safety, tolerability and efficacy of blisibimod plus standard of care, versus placebo plus standard of care.  A total of 547 patients with active SLE were randomized to receive one of three different doses of blisibimod or placebo (100 mg weekly, 200 mg weekly or 200 mg monthly) administered subcutaneously over a minimum 24-week treatment period, in addition to standard-of-care therapy. The study was conducted at multiple centers worldwide. 

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2012.  Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
2. Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
3. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
5. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
7. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
8. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
9. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
10. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
11. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... , April 1, 2015 International Isotopes Inc. ... fiscal year ended December 31, 2014.  The Company reports ... net loss, and positive cash flow for the year ... revenue in 2014 was approximately $7.5 million compared to ... of approximately 10%.  With the exception of the radiological ...
(Date:4/1/2015)... , April 1, 2015  Egalet Corporation (Nasdaq: ... pharmaceutical company focused on developing, manufacturing and marketing ... an offering of $60.0 million aggregate principal amount ... "notes") in a private placement to qualified institutional ... Act of 1933, as amended (the "Act"). Egalet ...
(Date:4/1/2015)... Md. , April 1, 2015 ... recruitment solutions for the clinical research industry, recently ... with a dermatology study that was falling quickly ... recruitment strategies and customized site support programs, increased ... and enrolling, and also increased the number of ...
Breaking Medicine Technology:International Isotopes Inc. Announces 2014 Year End Financial Results 2International Isotopes Inc. Announces 2014 Year End Financial Results 3International Isotopes Inc. Announces 2014 Year End Financial Results 4International Isotopes Inc. Announces 2014 Year End Financial Results 5International Isotopes Inc. Announces 2014 Year End Financial Results 6International Isotopes Inc. Announces 2014 Year End Financial Results 7Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 2Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 3Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 4Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 5Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 6Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 7CSSi Quadruples Screening Activity and Speeds Enrollment for Pediatric Dermatology Study 2
... 25, 2011 /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. (NYSE ... "Company"), a developer, manufacturer and distributor of botanical products, ... announced that the Company has recently hosted a technical ... of Traditional Chinese Medicine (TCM) and herbal medicine. ...
... Pharmaceuticals, LLC, today announced that data from studies evaluating ... a botulinum toxin type A free from accessory proteins, ... presented at the 115th Annual Meeting of the American ... These data include an extension of the Phase III, ...
Cached Medicine Technology:China Botanic Hosts Technical Exchange for Industry Research Experts 2China Botanic Hosts Technical Exchange for Industry Research Experts 3Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 2Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 3Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 4Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 5Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 6Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 7Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 8
(Date:4/1/2015)... Vancouver, BC (PRWEB) April 01, 2015 ... recently announced that she is now offering her patients ... and services. Patients can participate in “Beauty Days”, which ... year by Dr Roz Kamani’s Kitsilano Skin Care Clinic. ... will directly tell patients about the latest products and ...
(Date:4/1/2015)... April 01, 2015 GrassrootsHealth, an ... two continuing medical education (CME) courses about ... practitioners become more confident in measuring, prescribing, and ... completion of these CME courses, practitioners can apply ... CME courses available are “Vitamin D, Sunshine, Optimal ...
(Date:4/1/2015)... Tempaper has joined forces with the Muscular Dystrophy Association ... raise critical funds to help save and improve the ... States. , Throughout the month of April, anyone who ... receive free domestic ground shipping on all orders while ... children and adults affected by muscular dystrophy and related ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Like a ... is the scientific understanding of the potential causes of ... by the National Rosacea Society (NRS) to educate the ... treatable facial disorder now estimated to affect more than ... supported medical research on rosacea through its patient-funded research ...
(Date:4/1/2015)... FL (PRWEB) April 01, 2015 IQ ... growing health and nutritional supplement companies in the U.S., today ... the testing and quality control standards for its herbal supplements.* ... the supply chain to ensure the accuracy of labeling on ... industry veteran and IQ Formulations CEO Jay Cohen ...
Breaking Medicine News(10 mins):Health News:Dr Roz Kamani Now Offers Patients The Opportunity to Learn About Latest Products and Services 2Health News:GrassrootsHealth Launches CME Courses about Vitamin D 2Health News:GrassrootsHealth Launches CME Courses about Vitamin D 3Health News:Tempaper and MDA Team up in the Fight Against Muscle Disease 2Health News:Tempaper and MDA Team up in the Fight Against Muscle Disease 3Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 2Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 3Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 4Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 5Health News:IQ Formulations Applauds GNC for Enhancing Its Testing and Quality Control Processes for Herbal Supplements 2
... based on detainee interrogations finds that forms of ... physical pain—such as psychological// manipulation, deprivation, humiliation and ... distress and traumatic stress as physical torture. ... both physical and mental pain and suffering, according ...
... finds that nearly four out of five hospitalized children ... for adults//. The authors fear that treating children with ... measured the magnitude of off-label use of drugs in ... pediatrician specializing in infectious diseases at The Children’s Hospital ...
... increase polio vaccination in Nigeria has been a success, but ... the virus from northern states, say officials. ,The ... by the National Programme on Immunization (NPI) ¯ a government ... — to tackle polio in the 18 northern regions still ...
... a test for the early diagnosis of lung cancer. They hope ... cells// lining the airways leading to the lungs can be used ... ,Lung cancer is the most deadly form of the disease. In ... third most common in women. In 2002 about 37,700 new cases ...
... Yale University researchers have released results of a study ... caloric intake//, higher body weight, a decrease in calcium ... diabetes. ,The report also noted that studies ... to show detrimental effects from soft drinks than studies ...
... may not reflect the accurate amount of fat in a human ... as the standard for measuring the amount of fat in a ... by the square of their height. ,Generally, a BMI ... above indicates obesity. A person with a higher BMI is thought ...
Cached Medicine News:Health News:All Forms of Ill Treatment Cause Post Traumatic Stress Disorder-PTSD 2Health News:All Forms of Ill Treatment Cause Post Traumatic Stress Disorder-PTSD 3Health News:Prescribing Off Label Drugs for Children may Be Hazardous 2Health News:Prescribing Off Label Drugs for Children may Be Hazardous 3Health News:Nigerian Programme Increases Polio Immunisation 2Health News:Gene Cell Test may Aid Early Lung Cancer Diagnosis 2Health News:Yale Researchers Weigh the Science on Soft Drinks and Health 2
... The Health Trax System ... (RTLS), long range active RFID, ... in a single intergrated infrastructure. ... valuble assets and people in ...
... is part of the Kisses mother/infant ... The Kisses tag is given to ... been bonded with the Hugs tag ... tags remain electronically bonded throughout the ...
The PDC Smart® Key Fob can be programmed on demand using a 13.56 MHz RFID reader/writer and is ideal for long-term use applications such as electronic access control or loyalty programs....
... VeriMed can provide healthcare professionals ... whenhe or shecant speak, cant remember, ... option to affected individuals. The application ... individuals obtain a comparable level of ...
Medicine Products: